SageView Advisory Group
PVLA icon

SageView Advisory Group’s Palvella Therapeutics PVLA Stock Holding History

SageView Advisory Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6
Closed -$629 – 2570
2025
Q4 		$629 Buy
+6
New +$512 ﹤0.01% 2424

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SageView Advisory Group's PVLA Position: Q1 2026 in Review

SageView Advisory Group sold out of Palvella Therapeutics (PVLA) in Q1 2026, closing a stake of 6 shares — an estimated $629 sold.

SageView Advisory Group first reported a position in PVLA in Q4 2025 and held it in 1 quarter. The position peaked at $629 in Q4 2025. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • SageView Advisory Group reported no remaining Palvella Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 6 Palvella Therapeutics shares in Q1 2026, an estimated $629.
  • SageView Advisory Group first reported a position in Palvella Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Palvella Therapeutics position peaked at $629 in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.